FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024334311> ?p ?o ?g. }

• W2024334311 endingPage "1091" @default.
• W2024334311 startingPage "1084" @default.
• W2024334311 abstract "Ezetimibe is a lipid-lowering drug that inhibits the intestinal absorption of dietary and biliary cholesterol by blocking passage across the intestinal wall. The efficacy and safety of adding ezetimibe to ongoing statin therapy in patients with primary hypercholesterolemia was evaluated in a randomized, double-blind, placebo-controlled study. The study group included 769 adults (aged > or =18 years) with primary hypercholesterolemia who had not achieved National Cholesterol Education Program (NCEP) Adult Treatment Panel II goals with dietary alteration and statin monotherapy. Patients receiving a stable dose of a statin for > or =6 weeks were randomized to receive concurrent treatment with placebo (n = 390) or ezetimibe (n = 379), 10 mg/day, in addition to continuing their open-label statin for 8 weeks. The primary efficacy variable was the percent change in low-density lipoprotein (LDL) cholesterol from baseline with statin monotherapy to end point after intervention (secondary variables: high-density lipoprotein [HDL] cholesterol and triglycerides). Ongoing statin therapy plus ezetimibe led to changes of -25.1% for LDL cholesterol (HDL cholesterol +2.7%; triglycerides -14.0%) compared with LDL cholesterol -3.7% (p <0.001), HDL cholesterol +1.0% (p <0.05), and triglycerides -2.9% (p <0.001) for placebo added to ongoing statin therapy. Among patients not at LDL cholesterol goal at on-statin baseline, 71.5% receiving statin plus ezetimibe versus 18.9% receiving statin plus placebo reached goal at end point (odds ratio 23.7; p <0.001). The co-administration of statin and ezetimibe was generally well tolerated. Adding ezetimibe to ongoing statin therapy led to substantial additional reduction in LDL cholesterol levels, facilitating attainment of NCEP goals. Ezetimibe offers a new therapeutic option for patients receiving statins who require further reduction in LDL cholesterol." @default.
• W2024334311 created "2016-06-24" @default.
• W2024334311 creator A5014081492 @default.
• W2024334311 creator A5016481649 @default.
• W2024334311 creator A5053191013 @default.
• W2024334311 creator A5061030125 @default.
• W2024334311 creator A5070247016 @default.
• W2024334311 creator A5072124620 @default.
• W2024334311 creator A5072747894 @default.
• W2024334311 creator A5073233494 @default.
• W2024334311 creator A5078336416 @default.
• W2024334311 date "2002-11-01" @default.
• W2024334311 modified "2023-10-13" @default.
• W2024334311 title "Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia" @default.
• W2024334311 cites W1778499707 @default.
• W2024334311 cites W1993652095 @default.
• W2024334311 cites W1995116750 @default.
• W2024334311 cites W1995196487 @default.
• W2024334311 cites W1998997178 @default.
• W2024334311 cites W2072103134 @default.
• W2024334311 cites W2082069678 @default.
• W2024334311 cites W2094137191 @default.
• W2024334311 cites W2116404316 @default.
• W2024334311 cites W2118310760 @default.
• W2024334311 cites W2144755243 @default.
• W2024334311 cites W4238251256 @default.
• W2024334311 cites W4238377851 @default.
• W2024334311 doi "https://doi.org/10.1016/s0002-9149(02)02774-1" @default.
• W2024334311 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12423708" @default.
• W2024334311 hasPublicationYear "2002" @default.
• W2024334311 type Work @default.
• W2024334311 sameAs 2024334311 @default.
• W2024334311 citedByCount "454" @default.
• W2024334311 countsByYear W20243343112012 @default.
• W2024334311 countsByYear W20243343112013 @default.
• W2024334311 countsByYear W20243343112014 @default.
• W2024334311 countsByYear W20243343112015 @default.
• W2024334311 countsByYear W20243343112016 @default.
• W2024334311 countsByYear W20243343112017 @default.
• W2024334311 countsByYear W20243343112018 @default.
• W2024334311 countsByYear W20243343112019 @default.
• W2024334311 countsByYear W20243343112020 @default.
• W2024334311 countsByYear W20243343112021 @default.
• W2024334311 countsByYear W20243343112022 @default.
• W2024334311 countsByYear W20243343112023 @default.
• W2024334311 crossrefType "journal-article" @default.
• W2024334311 hasAuthorship W2024334311A5014081492 @default.
• W2024334311 hasAuthorship W2024334311A5016481649 @default.
• W2024334311 hasAuthorship W2024334311A5053191013 @default.
• W2024334311 hasAuthorship W2024334311A5061030125 @default.
• W2024334311 hasAuthorship W2024334311A5070247016 @default.
• W2024334311 hasAuthorship W2024334311A5072124620 @default.
• W2024334311 hasAuthorship W2024334311A5072747894 @default.
• W2024334311 hasAuthorship W2024334311A5073233494 @default.
• W2024334311 hasAuthorship W2024334311A5078336416 @default.
• W2024334311 hasConcept C126322002 @default.
• W2024334311 hasConcept C134018914 @default.
• W2024334311 hasConcept C142724271 @default.
• W2024334311 hasConcept C168563851 @default.
• W2024334311 hasConcept C203092338 @default.
• W2024334311 hasConcept C204787440 @default.
• W2024334311 hasConcept C27081682 @default.
• W2024334311 hasConcept C2776839432 @default.
• W2024334311 hasConcept C2778163477 @default.
• W2024334311 hasConcept C2778402494 @default.
• W2024334311 hasConcept C2778657065 @default.
• W2024334311 hasConcept C2780578515 @default.
• W2024334311 hasConcept C511355011 @default.
• W2024334311 hasConcept C71924100 @default.
• W2024334311 hasConcept C90924648 @default.
• W2024334311 hasConceptScore W2024334311C126322002 @default.
• W2024334311 hasConceptScore W2024334311C134018914 @default.
• W2024334311 hasConceptScore W2024334311C142724271 @default.
• W2024334311 hasConceptScore W2024334311C168563851 @default.
• W2024334311 hasConceptScore W2024334311C203092338 @default.
• W2024334311 hasConceptScore W2024334311C204787440 @default.
• W2024334311 hasConceptScore W2024334311C27081682 @default.
• W2024334311 hasConceptScore W2024334311C2776839432 @default.
• W2024334311 hasConceptScore W2024334311C2778163477 @default.
• W2024334311 hasConceptScore W2024334311C2778402494 @default.
• W2024334311 hasConceptScore W2024334311C2778657065 @default.
• W2024334311 hasConceptScore W2024334311C2780578515 @default.
• W2024334311 hasConceptScore W2024334311C511355011 @default.
• W2024334311 hasConceptScore W2024334311C71924100 @default.
• W2024334311 hasConceptScore W2024334311C90924648 @default.
• W2024334311 hasIssue "10" @default.
• W2024334311 hasLocation W20243343111 @default.
• W2024334311 hasLocation W20243343112 @default.
• W2024334311 hasOpenAccess W2024334311 @default.
• W2024334311 hasPrimaryLocation W20243343111 @default.
• W2024334311 hasRelatedWork W1966271903 @default.
• W2024334311 hasRelatedWork W2007911978 @default.
• W2024334311 hasRelatedWork W2024334311 @default.
• W2024334311 hasRelatedWork W2032483368 @default.
• W2024334311 hasRelatedWork W2041561513 @default.
• W2024334311 hasRelatedWork W2111908841 @default.
• W2024334311 hasRelatedWork W2333366670 @default.
• W2024334311 hasRelatedWork W2470248719 @default.

• next